CTOs on the Move

Neurelis

www.neurelis.com

 
Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company devoted to developing treatment options for epilepsy, while also investigating new treatment options for the unmet needs of central nervous system (CNS) disorders.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.neurelis.com
  • 11682 El Camino Real Suite 255
    San Diego, CA USA 92130
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Neurelis raised $114M on 03/10/2021

Similar Companies

Compass Health Center

Compass Health Center is a well known mental health care providing crisis support for individuals. Avail of our services in Chicago, Illinois!

harris pharmaceutical

harris pharmaceutical is a Fort Myers, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AnkaBehavioralHealth

All of Ankas programs share the same mission: to eliminate the impact of behavioral health problems for all people.

CARGO Therapeutics

CARGO Therapeutics is a biotechnology company that is developing and delivering CAR T cell therapies to cure more cancer patients. Their cell therapies focus on addressing the primary mechanisms of failure, or resistance and relapse, to the currently a...

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.